Oral vs injectable in this class — why the oral versions are a genuinely hard problem

Peptides are generally destroyed in the gut, which is why almost everything in this space is injectable. Getting an oral version to work is a real pharmaceutical achievement rather than a formulation convenience.

Two different approaches worth distinguishing:

1. Oral peptide with an absorption enhancer. The peptide is unchanged; a co-formulated agent helps it cross. Bioavailability is still low and variable, which is why administration conditions matter so much for these.

2. Small-molecule agonists. Not peptides at all — designed from the start to be orally available. Different manufacturing economics entirely, which matters for supply.

The second category is the more interesting one long term, because peptide manufacturing capacity has been a genuine constraint on this whole class.

Evidence tier: an oral peptide formulation is approved for specific indications; small-molecule agents are at various stages, some with phase 3 data.